Enlicitide decanoate is the first FDA-approved oral PCSK9 inhibitor. It is prescribed as an adjunct to diet and exercise to lower low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia or heterozygous familial hypercholesterolemia (HeFH). Other names for this substance include Lipfendra. Its PubChem CID is 172866837.
Enlicitide decanoate
| CAS No | 2861205-06-1 |
|---|---|
| Molecular Formula | C92H129FN14O17 |
| Molecular Weight | 1722.1 g/mol |
| Synonyms | decanoate;[6-[[(11S,17S,20S,23S,27S,39S,42S,63S,66R)-47-fluoro-20-[(1R)-1-hydroxyethyl]-17-[(4-methoxyphenyl)methyl]-11,63-dimethyl-10,16,19,22,30,40,58,61,64,67,70-undecaoxo-28-oxa-1,9,15,18,21,24,31,41,51,62,65,68-dodecazanonacyclo[37.18.11.23,6.124,42.133,37.144,51.011,15.023,27.045,50]triheptaconta-3(73),4,6(72),33,35,37(71),44(69),45(50),46,48-decaen-66-yl]methylamino]-6-oxohexyl]-trimethylazanium |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Enlicitide decanoate is the first FDA-approved oral PCSK9 inhibitor. It is prescribed as an adjunct to diet and exercise to lower low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia or heterozygous familial hypercholesterolemia (HeFH).
The listed CAS number is 2861205-06-1.
The listed molecular formula is C92H129FN14O17.
The listed molecular weight is 1722.1 g/mol.
The source lists Lipfendra.
The listed PubChem CID is 172866837.